307 related articles for article (PubMed ID: 31365334)
1. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
3. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
4. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
5. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
9. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
11. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis.
Parkes JE; Rothwell S; Oldroyd A; Chinoy H; Lamb JA;
Arthritis Res Ther; 2018 Jun; 20(1):117. PubMed ID: 29884237
[TBL] [Abstract][Full Text] [Related]
12. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
[TBL] [Abstract][Full Text] [Related]
13. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
14. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
15. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
16. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
18. Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.
Li X; Huang Y; Liu Y; Yan S; Li L; Cheng L; Li H; Zhan H; Zhang F; Li Y
Clin Rheumatol; 2023 Mar; 42(3):817-830. PubMed ID: 36357631
[TBL] [Abstract][Full Text] [Related]
19. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
Yang H; Peng Q; Yin L; Li S; Shi J; Zhang Y; Lu X; Shu X; Zhang S; Wang G
Arthritis Res Ther; 2017 Nov; 19(1):259. PubMed ID: 29178913
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]